17.66
Schlusskurs vom Vortag:
$17.47
Offen:
$17.44
24-Stunden-Volumen:
1.08M
Relative Volume:
0.39
Marktkapitalisierung:
$2.23B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-8.7401
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
-1.45%
1M Leistung:
+15.93%
6M Leistung:
+75.22%
1J Leistung:
+9.47%
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TXG
10 X Genomics Inc
|
17.65 | 2.21B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
232.04 | 39.30B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
76.28 | 13.71B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
45.62 | 8.60B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
93.25 | 7.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
35.34 | 6.23B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10x Genomics $TXG Shares Bought by Jump Financial LLC - MarketBeat
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders - Finviz
Why 10x Genomics Inc. stock appeals to analystsMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Russell Investments Group Ltd. Increases Stock Position in 10x Genomics $TXG - MarketBeat
Is 10x Genomics Inc. (1KJ) stock among top earnings playsJuly 2025 Highlights & Low Risk Entry Point Tips - Newser
Market Fear: Is CPSR stock trading at a premium valuation2025 Performance Recap & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus
TXG: Morgan Stanley Downgrades 10x Genomics, Raises Price Target - GuruFocus
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
TXG Technical Analysis & Signals — Is 10x Genomics, Inc. Stock a Buy or Sell? - Meyka
Is 10x Genomics Inc. stock safe for conservative investors2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - BỘ NỘI VỤ
Aug Levels: Why 10x Genomics Inc. stock could benefit from AI revolutionJuly 2025 Institutional & Verified Technical Trade Signals - BỘ NỘI VỤ
What sentiment indicators say about 10x Genomics Inc. stockQuarterly Profit Summary & Reliable Breakout Forecasts - BỘ NỘI VỤ
10x Genomics to Acquire Scale Biosciences (PR Newswire) - Aktiellt
Buy Signal: Is 10x Genomics Inc. stock safe for conservative investorsWeekly Earnings Recap & Reliable Momentum Entry Alerts - BỘ NỘI VỤ
How 10x Genomics Inc. stock responds to policy changes2025 Volatility Report & Risk Managed Trade Strategies - BỘ NỘI VỤ
10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing - marketscreener.com
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
Pres Hindson Surrenders 8,283 Of 10X Genomics Inc [TXG] - TradingView
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know - Finviz
CEO Saxonov Files To Sell 13,096 Of 10X Genomics Inc [TXG] - TradingView
CFO Taich Files To Sell 11,312 Of 10X Genomics Inc [TXG] - TradingView
Q3 2025 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN
10x Genomics, Inc.Common Stock (NQ: TXG - Markets Financial Content
Is 10x Genomics’ (TXG) New Asia-Pacific Consortium Key to Sustaining Its Leadership in Spatial Genomics? - Yahoo Finance
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - MSN
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
10X Genomics stock hits 52-week high at 17.7 USD By Investing.com - Investing.com India
10X Genomics stock hits 52-week high at 17.7 USD - Investing.com
Spatial Biology Market Analysis and Forecast, 2025-2035: - GlobeNewswire
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
How 10x Genomics Inc. (1KJ) stock trades pre earnings2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Total liabilities & shareholders' equities of 10x Genomics Inc Class A – HAM:1KJ - TradingView
Is 10x Genomics Inc. stock a buy before product launchesJuly 2025 Closing Moves & Safe Entry Zone Tips - newser.com
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium - StreetInsider
3 Reasons to Avoid TXG and 1 Stock to Buy Instead - Finviz
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
TXG (10x Genomics) Inventory-to-Revenue : 0.44 (As of Sep. 2025) - GuruFocus
10x Genomics Announces Chief Legal Officer Retirement - The Globe and Mail
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026 - MarketScreener
10X Genomics Stock Soars 17.31%, Hits Intraday High of $15.26 - Markets Mojo
10x Genomics Inc Class A Earnings and Revenue – HAM:1KJ - TradingView
How 10x Genomics Inc. (1KJ) stock valuation compares with sectorChart Signals & Safe Entry Point Alerts - newser.com
Why 10x Genomics Inc. (1KJ) stock attracts wealthy investorsSell Signal & Verified Stock Trade Ideas - newser.com
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 - Eastern Progress
TXG announces CLO retirement; Randy Wu to serve as General Counsel - Stock Titan
10x Genomics, Inc. (TXG) Stock Price Quote Today & Current Price Chart - Capital.com
10x Genomics (TXG): Assessing Valuation After Strong Earnings, Upbeat Forecast and New Product Launch - Yahoo Finance
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
Nov 24 '25 |
Sale |
19.00 |
8,283 |
157,363 |
432,605 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '25 |
Sale |
19.00 |
13,261 |
251,936 |
1,021,556 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):